BNP Paribas Financial Markets
ENTA icon

BNP Paribas Financial Markets’s Enanta Pharmaceuticals ENTA Stock Holding History

BNP Paribas Financial Markets’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$212K Sell
16,809
-83,075
-83% -$1.11M ﹤0.01% 4026
2025
Q4 		$1.58M Buy
99,884
+80,064
+404% +$1.02M ﹤0.01% 2795
2025
Q3 		$237K Sell
19,820
-19,436
-50% -$155K ﹤0.01% 3928
2025
Q2 		$297K Sell
39,256
-8,351
-18% -$50.2K ﹤0.01% 3609
2025
Q1 		$263K Sell
47,607
-23,497
-33% -$145K ﹤0.01% 3558
2024
Q4 		$409K Buy
71,104
+35,695
+101% +$342K ﹤0.01% 3417
2024
Q3 		$367K Buy
35,409
+651
+2% +$8.51K ﹤0.01% 2979
2024
Q2 		$451K Buy
34,758
+10,075
+41% +$136K ﹤0.01% 2723
2024
Q1 		$431K Sell
24,683
-24,776
-50% -$328K ﹤0.01% 2920
2023
Q4 		$465K Sell
49,459
-5,990
-11% -$55.8K ﹤0.01% 2830
2023
Q3 		$619K Buy
55,449
+8,596
+18% +$138K ﹤0.01% 2603
2023
Q2 		$1M Buy
46,853
+23,695
+102% +$699K ﹤0.01% 2195
2023
Q1 		$937K Sell
23,158
-191
-0.8% -$9.12K ﹤0.01% 2365
2022
Q4 		$1.09M Sell
23,349
-3,012
-11% -$137K ﹤0.01% 2116
2022
Q3 		$1.37M Buy
26,361
+20,158
+325% +$1.18M ﹤0.01% 2239
2022
Q2 		$293K Sell
6,203
-2,240
-27% -$122K ﹤0.01% 2922
2022
Q1 		$601K Sell
8,443
-16,302
-66% -$1.06M ﹤0.01% 2649
2021
Q4 		$1.85M Buy
24,745
+5,911
+31% +$464K ﹤0.01% 2105
2021
Q3 		$1.07M Buy
18,834
+11,326
+151% +$560K ﹤0.01% 2333
2021
Q2 		$330K Sell
7,508
-316
-4% -$15.5K ﹤0.01% 2716
2021
Q1 		$386K Buy
7,824
+4,818
+160% +$240K ﹤0.01% 2716
2020
Q4 		$127K Sell
3,006
-1,839
-38% -$80.9K ﹤0.01% 3102
2020
Q3 		$222K Sell
4,845
-18,674
-79% -$905K ﹤0.01% 2718
2020
Q2 		$1.18M Sell
23,519
-10,106
-30% -$523K ﹤0.01% 1721
2020
Q1 		$1.73M Buy
33,625
+29,897
+802% +$1.59M ﹤0.01% 1568
2019
Q4 		$230K Buy
3,728
+1,036
+38% +$64.2K ﹤0.01% 2891
2019
Q3 		$162K Buy
2,692
+816
+43% +$60.6K ﹤0.01% 2860
2019
Q2 		$158K Sell
1,876
-1,622
-46% -$146K ﹤0.01% 2765
2019
Q1 		$334K Buy
3,498
+3,492
+58,200% +$313K ﹤0.01% 2368
2018
Q4 		$425 Sell
6
-548
-99% -$42K ﹤0.01% 4017
2018
Q3 		$47.3K Sell
554
-7,633
-93% -$765K ﹤0.01% 3065
2018
Q2 		$949K Sell
8,187
-4,394
-35% -$438K ﹤0.01% 1766
2018
Q1 		$1.02M Sell
12,581
-7,847
-38% -$604K ﹤0.01% 1722
2017
Q4 		$1.2M Buy
20,428
+12,972
+174% +$650K ﹤0.01% 1837
2017
Q3 		$349K Buy
7,456
+3,047
+69% +$122K ﹤0.01% 2163
2017
Q2 		$159K Buy
4,409
+1,702
+63% +$54.4K ﹤0.01% 2581
2017
Q1 		$83.4K Sell
2,707
-269
-9% -$8.38K ﹤0.01% 2557
2016
Q4 		$99.7K Buy
2,976
+758
+34% +$21.7K ﹤0.01% 2525
2016
Q3 		$59K Sell
2,218
-2,200
-50% -$51.1K ﹤0.01% 2356
2016
Q2 		$97.4K Buy
4,418
+2,355
+114% +$61.6K ﹤0.01% 2125
2016
Q1 		$60.6K Sell
2,063
-1,731
-46% -$48.2K ﹤0.01% 1946
2015
Q4 		$125K Buy
3,794
+213
+6% +$6.94K ﹤0.01% 2182
2015
Q3 		$129K Buy
3,581
+2,249
+169% +$96.6K ﹤0.01% 2222
2015
Q2 		$59.9K Buy
1,332
+1,083
+435% +$42.1K ﹤0.01% 2380
2015
Q1 		$7.62K Buy
+249
New +$9.69K ﹤0.01% 2902
2014
Q4 		– Sell
-811
Closed -$32.1K – 2340
2014
Q3 		$32.1K Buy
811
+777
+2,285% +$31K ﹤0.01% 2858
2014
Q2 		$1.46K Buy
+34
New +$1.3K ﹤0.01% 3274

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BNP Paribas Financial Markets's ENTA Position: Q1 2026 in Review

BNP Paribas Financial Markets reduced its Enanta Pharmaceuticals (ENTA) stake by 83% in Q1 2026, selling an estimated $1.11M and leaving 16,809 shares worth $212K. The position accounts for ﹤0.01% of the portfolio, ranked #4026.

BNP Paribas Financial Markets first reported a position in ENTA in Q2 2014 and has held it in 47 quarters since. The position peaked at $1.85M in Q4 2021. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • BNP Paribas Financial Markets held 16,809 shares of Enanta Pharmaceuticals worth $212K as of Q1 2026.
  • BNP Paribas Financial Markets sold 83,075 Enanta Pharmaceuticals shares in Q1 2026, an estimated $1.11M.
  • Enanta Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4026 holding.
  • BNP Paribas Financial Markets first reported a position in Enanta Pharmaceuticals in Q2 2014 and has held it in 47 quarters since.
  • BNP Paribas Financial Markets's Enanta Pharmaceuticals position peaked at $1.85M in Q4 2021.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.